IBRX vs PVLA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IBRX Captures Institutional Edge (3โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ImmunityBio, Inc. Common Stock (IBRX) driven by superior Valuation, Growth & Margin, Momentum & Technical while PVLA counters with relative strength in Options & Structure. Fundamentally, IBRX trades at 66.7x Forward P/E with -150.2% operating margin (+52.3% YoY revenue) versus PVLA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, IBRX sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against PVLA sits in CONSOLIDATION (2nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | IBRX Revenue | PVLA Revenue | IBRX Op. Margin | PVLA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | $30M | -209338.3% | -113.1% | PVLA |
| FY2019 | $0M | $40M | -7095.9% | -62.2% | PVLA |
| FY2020 | $0M | $30M | -36509.1% | -115.7% | PVLA |
| FY2021 | $0M | $30M | -35361.9% | -165.0% | PVLA |
| FY2022 | $0M | $30M | -146374.2% | -167.8% | PVLA |
| FY2023 | $0M | $40M | -58239.5% | -27.7% | PVLA |
| FY2024 | $10M | N/A | -2334.2% | N/A | IBRX |
| FY2025 | $110M | N/A | -226.0% | N/A | IBRX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IBRX | PVLA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $6.5B | $2.2B | Larger Scale | IBRX |
| Trailing P/E Ratio Valuation | 66.7x | N/M | Lower Multiple | IBRX |
| Forward P/E Ratio Valuation | 66.7x | N/M | Lower Multiple | IBRX |
| Revenue Growth (YoY) Growth | +52.3% | +0.0% | Higher Growth | IBRX |
| Operating Margin (TTM) Profitability | -150.2% | 0.0% | Higher Margin | PVLA |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | 0.0% | -63.4% | Higher ROE | IBRX |
| 52-Week Range Position Momentum | 39% ($2โ$12) | 68% ($72โ$180) | Stronger Trend | PVLA |
| Beta / 30D Volatility Risk Regime | 1.68ฮฒ ยท 103% Vol | 1.66ฮฒ ยท 75% Vol | Lower Realized Risk | PVLA |
| Unified Institutional Score Composite Signal | 52.8 / 100 (HOLD) | 48.2 / 100 (HOLD) | Higher Composite | IBRX |